Supernus Pharmaceuticals (NASDAQ:SUPN) PT Lowered to $42.00
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its target price trimmed by Piper Sandler from $43.00 to $42.00 in a report published on Wednesday, Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in […]
More Stories
Kavango Resources (LON:KAV) Shares Up 15.3% – Still a Buy?
Kavango Resources Plc (LON:KAV – Get Free Report)’s stock price shot up 15.3% on Monday . The stock traded as...
Highland Copper (CVE:HI) Stock Price Down 17.6% – Time to Sell?
Shares of Highland Copper Company Inc. (CVE:HI – Get Free Report) fell 17.6% on Monday . The stock traded as...
Highland Copper (CVE:HI) Trading Down 17.6% – What’s Next?
Highland Copper Company Inc. (CVE:HI – Get Free Report)’s stock price fell 17.6% on Monday . The company traded as...
National Research Co. (NRC) To Go Ex-Dividend on December 27th
National Research Co. (NASDAQ:NRC – Get Free Report) announced a quarterly dividend on Friday, October 25th,Zacks Dividends reports. Stockholders of...
Directa Plus (LON:DCTA) Sets New 52-Week Low – What’s Next?
Directa Plus Plc (LON:DCTA – Get Free Report) shares hit a new 52-week low on Monday . The stock traded...
Marwyn Value Investors (LON:MVI) Reaches New 1-Year High – Should You Buy?
Marwyn Value Investors (LON:MVI – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Monday...